Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 20:05 | 2026-05-20 | AZN | ASTRAZENECA PLC | Sharma Mani | Officer | SELL | $185.78 | 11,893 | $2,209,482 | 19,262 |
| 2026-05-22 20:15 | 2026-05-21 | ARVN | ARVINAS, INC. | Teel Randy | Director, Officer | SELL | $9.04 | 2,209 | $19,962 | 285,009 |
| 2026-05-22 20:05 | 2026-05-20 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $64.43 | 1,563 | $100,712 | 490,000 |
| 2026-05-22 20:05 | 2026-05-20 | PVLA | PALVELLA THERAPEUTICS, INC. | Goin Kathleen | Officer | OPT+S | $110.56 | 4,302 | $475,631 | 0 |
| 2026-05-22 20:14 | 2026-05-21 | ARDX | ARDELYX, INC. | Brady James Parker | Officer | SELL | $6.27 | 1,846 | $11,570 | 261,066 |
| 2026-05-22 20:12 | 2026-05-21 | ARDX | ARDELYX, INC. | Foster Eric Duane | Officer | SELL | $6.27 | 7,998 | $50,127 | 417,972 |
| 2026-05-22 20:10 | 2026-05-21 | ARDX | ARDELYX, INC. | Kelliher Mike | Officer | SELL | $6.27 | 7,248 | $45,427 | 357,418 |
| 2026-05-22 20:09 | 2026-05-21 | ARDX | ARDELYX, INC. | Williams Laura A | Officer | SELL | $6.27 | 6,989 | $43,804 | 429,093 |
| 2026-05-22 20:05 | 2026-05-21 | KURA | Kura Oncology, Inc. | Powl Brian T. | Officer | SELL | $11.00 | 10,000 | $110,000 | 173,614 |
| 2026-05-22 20:10 | 2026-05-20 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Director | BUY | $17.12 | 2,500 | $42,800 | 18,000 |
| 2026-05-22 20:06 | 2026-05-21 | ARDX | ARDELYX, INC. | RAAB MICHAEL | Director, Officer | SELL | $6.27 | 54,748 | $343,133 | 1,720,033 |
| 2026-05-22 20:25 | 2026-05-22 | INSM | INSMED Inc | Smith Michael Alexander | Officer | SELL | $108.47 | 6,149 | $666,982 | 41,613 |
| 2026-05-22 23:00 | 2026-05-20 | BTAI | BioXcel Therapeutics, Inc. | Mehta Vimal | Director, Officer | OPT+S | $1.09 | 19,419 | $21,108 | 69,598 |
| 2026-05-22 23:01 | 2026-05-20 | BTAI | BioXcel Therapeutics, Inc. | Steinhart Richard I | Officer | OPT+S | $1.09 | 6,845 | $7,427 | 26,300 |
| 2026-05-22 23:02 | 2026-05-20 | BTAI | BioXcel Therapeutics, Inc. | Rodriguez Javier | Officer | OPT+S | $1.08 | 6,560 | $7,111 | 26,803 |
| 2026-05-22 23:02 | 2026-05-20 | BTAI | BioXcel Therapeutics, Inc. | Yocca Frank | Officer | OPT+S | $1.09 | 6,845 | $7,427 | 26,175 |
| 2026-05-22 22:25 | 2026-05-22 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $30.27 | 200,000 | $6,054,000 | 1,613,063 |
| 2026-05-22 22:19 | 2026-05-20 | GYRE | GYRE THERAPEUTICS, INC. | Ye Weiguo | Officer | OPT+S | $6.15 | 22,220 | $136,653 | 700,000 |
| 2026-05-22 22:01 | 2026-05-22 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Levy Richard S | Director | SELL | $515.44 | 5,682 | $2,928,716 | 22,015 |
| 2026-05-22 21:24 | 2026-05-22 | ABEO | ABEONA THERAPEUTICS INC. | Alvino Mark | Director | SELL | $5.46 | 6,500 | $35,463 | 77,565 |
| 2026-05-22 21:16 | 2026-05-21 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $564.11 | 10,000 | $5,641,130 | 18,876 |
| 2026-05-22 20:54 | 2026-05-21 | ORKA | Oruka Therapeutics, Inc. | Dambkowski Carl | Director | OPT+S | $58.97 | 105,000 | $6,191,367 | 73,743 |
| 2026-05-22 20:59 | 2026-05-19 | SER | Serina Therapeutics, Inc. | Marshall Richard Peter | Director | BUY | $1.65 | 12,183 | $20,102 | 12,183 |
| 2026-05-22 20:46 | 2026-05-21 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $564.11 | 9,500 | $5,359,012 | 40,513 |
| 2026-05-22 20:15 | 2026-05-21 | ARDX | ARDELYX, INC. | Bishop John E | Officer | SELL | $6.27 | 2,306 | $14,453 | 336,845 |
| 2026-05-22 20:17 | 2026-05-21 | ARDX | ARDELYX, INC. | Hohenleitner Susan | Officer | SELL | $6.27 | 1,455 | $9,119 | 229,078 |
| 2026-05-22 20:18 | 2026-05-21 | ARDX | ARDELYX, INC. | Reilly Joseph James | Officer | SELL | $6.27 | 3,719 | $23,309 | 149,836 |
| 2026-05-22 18:54 | 2026-05-20 | PHVS | Pharvaris N.V. | Bjork Elisabeth | Director | OPT+S | $29.32 | 10,000 | $293,166 | 15,167 |
| 2026-05-22 15:59 | 2026-05-21 | NATR | NATURES SUNSHINE PRODUCTS INC | Brower Nathan G | Officer | SELL | $21.84 | 12,015 | $262,408 | 43,438 |
| 2026-05-21 20:15 | - | ZOMDF | Zomedica Corp. | Klass Russell Kevin | BUY | $0.11 | 216,899 | $22,796 | 6,001,000 | |
| 2026-05-21 20:06 | 2026-05-19 | RCKT | ROCKET PHARMACEUTICALS, INC. | Shah Gaurav | Officer | SELL | $3.01 | 2,409 | $7,261 | 1,040,918 |
| 2026-05-21 20:06 | 2026-05-19 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $3.01 | 662 | $1,995 | 677,977 |
| 2026-05-21 20:06 | 2026-05-19 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $3.01 | 384 | $1,157 | 89,780 |
| 2026-05-22 01:20 | 2026-05-20 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $52.75 | 13,684 | $721,838 | 18,197 |
| 2026-05-22 00:11 | 2026-05-20 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | BUY | $1.87 | 76,344 | $142,779 | 3,364,883 |
| 2026-05-21 22:26 | 2026-05-19 | NKTR | NEKTAR THERAPEUTICS | ROBIN HOWARD W | Director, Officer | SELL | $65.51 | 444 | $29,086 | 75,045 |
| 2026-05-21 22:26 | 2026-05-19 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $65.51 | 199 | $13,036 | 20,975 |
| 2026-05-21 22:30 | 2026-05-18 | AVIR | Atea Pharmaceuticals, Inc. | Murphy Polly A. | Director | BUY | $4.17 | 6,100 | $25,446 | 92,145 |
| 2026-05-21 21:08 | 2026-05-19 | INM | InMed Pharmaceuticals Inc. | ADAR1 Capital Management, LLC | 10% owner | BUY | $1.54 | 468,551 | $721,569 | 800,000 |
| 2026-05-21 20:31 | 2026-05-20 | TRDA | Entrada Therapeutics, Inc. | Zeiher Bernhardt G | Director | BUY | $5.86 | 5,000 | $29,316 | 5,000 |
| 2026-05-21 20:33 | 2026-05-21 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $562.82 | 8,300 | $4,671,399 | 45,172 |
| 2026-05-21 20:34 | 2026-05-20 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $565.98 | 9,500 | $5,376,815 | 40,513 |
| 2026-05-21 20:15 | - | ZOMDF | Zomedica Corp. | POWERS JOHNNY D | Director | BUY | $0.10 | 200,000 | $20,600 | 4,425,000 |
| 2026-05-21 16:08 | 2026-05-13 | ANL | Adlai Nortye Ltd. | LU YANG | Director, Officer, 10% owner | SELL | $13.18 | 10 | $132 | 99,990 |
| 2026-05-21 11:00 | 2026-05-19 | RNXT | RenovoRx, Inc. | VOLL MARK | Officer | BUY | $0.79 | 25,000 | $19,690 | 142,380 |
| 2026-05-20 20:07 | 2026-05-18 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | Director, Officer | OPT+S | $20.04 | 15,000 | $300,579 | 362,152 |
| 2026-05-20 20:05 | 2026-05-19 | KURA | Kura Oncology, Inc. | FORD KATHLEEN | Officer | SELL | $9.08 | 2,257 | $20,483 | 153,560 |
| 2026-05-20 20:05 | 2026-05-19 | KURA | Kura Oncology, Inc. | Powl Brian T. | Officer | SELL | $9.21 | 339 | $3,122 | 183,614 |
| 2026-05-20 20:05 | 2026-05-18 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | Officer | SELL | $9.38 | 2,256 | $21,160 | 226,931 |
| 2026-05-20 20:05 | 2026-05-18 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Freund John Gordon | Director | SELL | $34.05 | 20 | $681 | 83,952 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.